FMS - Better Buy: Cara Therapeutics vs. Fresenius
Choosing between a stock that has a lot of upside and one that offers stability can be a difficult decision for investors, and it could make a significant impact on overall returns. Cara Therapeutics (NASDAQ: CARA) and Fresenius Medical Care AG & Co. (NYSE: FMS) are two companies that are in very different stages in their businesses and come with very different risks.
They've achieved similar returns in 2019, but there's no guarantee that will be the case in future years. Let's take a closer look at the two companies and see which is the better investment option today.
Heading into December, Cara Therapeutics was having a terrific year. At that point, the stock was up around 80% since January, and things were looking good. With its drug Korsuva making progress in phase 3 trials and Oral Korsuva in phase 2 and showing potential as well, the stock was on track to continue climbing even higher.